These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9673053)

  • 21. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-pertussis components of combination vaccines: problems with potency testing.
    Sesardic D; Dawes CS; Mclellan K; Durrani Z; Yost SE; Corbel MJ
    Biologicals; 1999 Jun; 27(2):177-81. PubMed ID: 10600209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Composition of acellular pertussis and combination vaccines: a general review.
    Jadhav SS; Gairola S
    Biologicals; 1999 Jun; 27(2):105-10. PubMed ID: 10600195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.
    Denoël PA; Goldblatt D; de Vleeschauwer I; Jacquet JM; Pichichero ME; Poolman JT
    Clin Vaccine Immunol; 2007 Oct; 14(10):1362-9. PubMed ID: 17699836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.
    Pietrzyk JJ; Wysocki J; Pejcz J; Galaj A; Majda-Stanislawska E; Käyhty H; Thierry-Carstensen B; Jensen AM
    Vaccine; 2008 Sep; 26(41):5296-303. PubMed ID: 18675870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
    Mawas F; Newman G; Burns S; Corbel MJ
    J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants.
    Bavdekar SB; Maiya PP; Subba Rao SD; Datta SK; Bock HL
    Indian Pediatr; 2007 Jul; 44(7):505-10. PubMed ID: 17684303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of recent clinical trials of acellular pertussis vaccines.
    Miller E
    Biologicals; 1999 Jun; 27(2):79-86. PubMed ID: 10600188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety.
    Mallet E; Belohradsky BH; Lagos R; Gothefors L; Camier P; Carrière JP; Kanra G; Hoffenbach A; Langue J; Undreiner F; Roussel F; Reinert P; Flodmark CE; Stojanov S; Liese J; Levine MM; Muñoz A; Schödel F; Hessel L;
    Vaccine; 2004 Mar; 22(11-12):1343-57. PubMed ID: 15063556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Romero A; Lopez G; Dal-Ré R
    Pediatrics; 2005 Dec; 116(6):1292-8. PubMed ID: 16322149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future combined vaccines.
    Bégué P; Grimprel E
    J Infect Dis; 1996 Nov; 174 Suppl 3():S295-7. PubMed ID: 8896533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definition of acceptable levels for safety and potential problems.
    Salmaso S
    Biologicals; 1994 Dec; 22(4):407-8. PubMed ID: 7779370
    [No Abstract]   [Full Text] [Related]  

  • 39. New developments in paediatric vaccines.
    Gledhill E
    Prof Care Mother Child; 1996; 6(5):117-8. PubMed ID: 9077257
    [No Abstract]   [Full Text] [Related]  

  • 40. [Immunisation: leaps into the future. Combined vaccines (I)].
    Puig-Barberà J; Díez Domingo J
    Aten Primaria; 2003 Apr; 31(7):453-7. PubMed ID: 12735889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.